Table 4.
The effect of VAP on clinical outcomes in study patients
| Outcome (s) | Early VAP | OR [95 % CI] | P | Late VAP | OR [95 % CI] | P value | ||
|---|---|---|---|---|---|---|---|---|
| Yes | No | Yes | No | |||||
| DOMV, mean ± SD | 10.6 ± 4 | 8.6 ± 5.5 | 0.17 | 13.3 ± 1.4 | 8.2 ± 4.8 | <0.0001 | ||
| Duration of ICU stay, mean ± SD | 22.9 ± 15.5 | 20 ± 17.9 | 0.54 | 33 ± 17 | 16.5 ± 13.4 | <0.0001 | ||
| Duration of hospital stay, mean ± SD | 25.5 ± 17 | 24 ± 23 | 0.78 | 37 ± 22 | 19.3 ± 15.6 | 0.002 | ||
| Days on vasopressor therapy, mean ± SD | 3.4 ± 4 | 5.5 ± 5 | 0.13 | 8.3 ± 5.3 | 2.4 ± 3 | <0.0001 | ||
| Incidence of new infection, n/N | 8/33 | 8/21 | 0.6 [0.18–2] | 0.60 | 13/19 | 3/35 | 46 [8–259] | <0.0001 |
| Incidence of ARDS, n/N | 3/33 | 4/21 | 0.57 [0.11–2.8] | 0.47 | 4/19 | 3/35 | 3.9 [0.76–20] | 0.087 |
| Overall mortality, n/N | 16/33 | 13/21 | 0.97 [0.33–2.8] | 0.54 | 14/19 | 15/35 | 10 [1.8–47] | 0.001 |
DOMV duration of mechanical ventilation, ICU intensive care unit, VAP ventilator-associated pneumonia, ARDS acute respiratory distress syndrome, SD standard deviation, OR odds ratio